• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先用HIV-1 Gag蛋白和胞嘧啶磷酸鸟苷寡脱氧核苷酸进行初免-加强免疫,随后接种腺病毒,可诱导持续且强烈的体液免疫和细胞免疫反应。

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

作者信息

Tritel Marc, Stoddard Amy M, Flynn Barbara J, Darrah Patricia A, Wu Chang-you, Wille Ulrike, Shah Javeed A, Huang Yue, Xu Ling, Betts Michael R, Nabel Gary J, Seder Robert A

机构信息

Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA.

出版信息

J Immunol. 2003 Sep 1;171(5):2538-47. doi: 10.4049/jimmunol.171.5.2538.

DOI:10.4049/jimmunol.171.5.2538
PMID:12928404
Abstract

A prophylactic vaccine for HIV-1 will probably require the induction and maintenance of both humoral and cellular immunity. One current strategy to achieve such long term immune responses is a prime-boost vaccination approach using a DNA priming inoculation, followed by recombinant viral boost. In this report we use a novel prime-boost approach in which the priming injections consist of recombinant HIV-1 Gag protein mixed with cytosine phosphate guanosine oligodeoxynucleotide (CpG ODN), followed by recombinant adenoviral boost expressing HIV-1 Gag. Analysis of the immune responses indicates that HIV-1 Gag protein plus CpG ODN immunization alone induces potent humoral as well as Th1 and CD8+ T cell responses. Boosting with recombinant adenovirus strikingly enhances CD8+, but not Th1, T cell responses, resulting in CD8+ T cell responses far greater in magnitude than Th1 responses. Furthermore, the Th1 and CD8+ T cell responses following prime-boost immunization were seen in both lymphoid and peripheral mucosal organs and were sustained over several months. Together, these data suggest a new immunization approach for elicitation of long term humoral and cellular immune responses.

摘要

一种用于HIV-1的预防性疫苗可能需要诱导和维持体液免疫和细胞免疫。目前实现这种长期免疫反应的一种策略是采用初免-加强疫苗接种方法,即先用DNA初免接种,随后进行重组病毒加强免疫。在本报告中,我们采用了一种新型的初免-加强方法,其中初免注射由重组HIV-1 Gag蛋白与胞嘧啶磷酸鸟嘌呤寡脱氧核苷酸(CpG ODN)混合组成,随后用表达HIV-1 Gag的重组腺病毒进行加强免疫。对免疫反应的分析表明,单独使用HIV-1 Gag蛋白加CpG ODN免疫可诱导强烈的体液免疫以及Th1和CD8+ T细胞反应。用重组腺病毒加强免疫显著增强了CD8+ T细胞反应,但未增强Th1 T细胞反应,导致CD8+ T细胞反应的强度远大于Th1反应。此外,初免-加强免疫后的Th1和CD8+ T细胞反应在淋巴器官和外周黏膜器官中均可见,且持续数月。总之,这些数据提示了一种引发长期体液免疫和细胞免疫反应的新免疫方法。

相似文献

1
Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.先用HIV-1 Gag蛋白和胞嘧啶磷酸鸟苷寡脱氧核苷酸进行初免-加强免疫,随后接种腺病毒,可诱导持续且强烈的体液免疫和细胞免疫反应。
J Immunol. 2003 Sep 1;171(5):2538-47. doi: 10.4049/jimmunol.171.5.2538.
2
Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.一种多价DNA初免/蛋白加强HIV-1疫苗引发的细胞免疫反应的临床前评估。
Virology. 2006 Mar 1;346(1):151-68. doi: 10.1016/j.virol.2005.10.038. Epub 2005 Dec 2.
3
Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.用与TLR7/8激动剂偶联的HIV-1 Gag蛋白进行免疫可导致产生HIV-1 Gag特异性Th1和CD8 + T细胞反应。
J Immunol. 2005 Jun 15;174(12):7676-83. doi: 10.4049/jimmunol.174.12.7676.
4
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.通过使用异源E1缺失腺病毒疫苗载体的初免-加强方案诱导CD8 + T细胞针对HIV-1抗原的反应。
J Immunol. 2003 Dec 15;171(12):6774-9. doi: 10.4049/jimmunol.171.12.6774.
5
Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.经鼻递送改良痘苗病毒安卡拉(MVA)载体后诱导生殖道HIV免疫:DNA初免-改良痘苗病毒安卡拉加强免疫方案后的免疫原性增强
J Immunol. 2004 May 15;172(10):6209-20. doi: 10.4049/jimmunol.172.10.6209.
6
Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.黏膜佐剂增强的重组流感病毒载体疫苗在小鼠中诱导针对 HIV-1 的 T 细胞和抗体应答。
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00059-21.
7
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates.Toll样受体激动剂影响非人灵长类动物初次-加强免疫后记忆性T细胞反应的强度和质量。
J Exp Med. 2006 May 15;203(5):1249-58. doi: 10.1084/jem.20052433. Epub 2006 Apr 24.
8
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.鼻内接种具有复制能力的仙台病毒载体1型人类免疫缺陷病毒(HIV-1) gag疫苗的安全性和免疫原性的首次人体评估:在初免-加强免疫方案中诱导强效T细胞或抗体反应
J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.
9
Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.基于表达中国HIV-1 B亚型gag基因的DNA、腺病毒和仙台病毒载体的初免-加强-加强策略诱导的强效特异性免疫反应。
Vaccine. 2008 Nov 11;26(48):6124-31. doi: 10.1016/j.vaccine.2008.09.017. Epub 2008 Sep 22.
10
Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.在小鼠中使用重组牛分枝杆菌卡介苗和携带HIV-1 CRF01_AE gag的重组痘苗病毒DIs进行初免-加强免疫接种:免疫途径的影响
Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):273-81.

引用本文的文献

1
LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.LEISH2b——一项2b期研究,旨在评估利什曼原虫疫苗ChAd63-KH在黑热病后皮肤利什曼病中的安全性、有效性和免疫原性。
Wellcome Open Res. 2022 Aug 3;7:200. doi: 10.12688/wellcomeopenres.17951.1. eCollection 2022.
2
Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.了解腺病毒衣壳的进入后分拣;改变疫苗载体特性的机会。
Viruses. 2021 Jun 24;13(7):1221. doi: 10.3390/v13071221.
3
Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.
通过 DNA 疫苗初免 MVA 加强型 C 亚群预防性疫苗在印度进行的 I 期临床试验中诱导和维持双功能(IFN-γ+IL-2+和 IL-2+TNF-α+)T 细胞应答。
PLoS One. 2019 Mar 28;14(3):e0213911. doi: 10.1371/journal.pone.0213911. eCollection 2019.
4
Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.优化免疫策略以诱导抗原特异性CD4和CD8 T细胞应答,从而抵御细胞内寄生虫感染。
Clin Vaccine Immunol. 2016 Sep 6;23(9):785-94. doi: 10.1128/CVI.00251-16. Print 2016 Sep.
5
Age Dependence of Immunity Induced by a Candidate Universal Influenza Vaccine in Mice.候选通用流感疫苗在小鼠中诱导的免疫的年龄依赖性
PLoS One. 2016 Apr 7;11(4):e0153195. doi: 10.1371/journal.pone.0153195. eCollection 2016.
6
Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.用甘露糖化聚乙烯亚胺作为 DNA 疫苗佐剂的异源 DNA 初免-腺病毒加强免疫接种增强对 HIV-1 的免疫应答。
Int J Nanomedicine. 2013;8:1843-54. doi: 10.2147/IJN.S43827. Epub 2013 May 9.
7
Increased toll-like receptor signaling pathways characterize CD8+ cells in rapidly progressive SIV infection.Toll 样受体信号通路的增加特征在于快速进展性 SIV 感染中的 CD8+ 细胞。
Biomed Res Int. 2013;2013:796014. doi: 10.1155/2013/796014. Epub 2012 Dec 27.
8
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.一种新型 HIV 疫苗,经 IC31 佐剂后可诱导出强大且持久的体液和细胞免疫。
PLoS One. 2012;7(7):e42163. doi: 10.1371/journal.pone.0042163. Epub 2012 Jul 25.
9
Vaccine design for CD8 T lymphocyte responses.针对 CD8 T 淋巴细胞反应的疫苗设计。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252. doi: 10.1101/cshperspect.a007252.
10
Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.交替使用质粒 DNA 和表达登革热病毒 2 型 E 蛋白的活病毒载体疫苗进行初免-加强免疫可诱导出不同的体液和细胞免疫应答。
Immune Netw. 2011 Oct;11(5):268-80. doi: 10.4110/in.2011.11.5.268. Epub 2011 Oct 31.